Medindia

X

Mylan Announces Final FDA Approval for Fluoxetine Capsules

by Medindia Content Team on  May 30, 2007 at 8:30 PM Drug News   - G J E 4
Mylan Announces Final FDA Approval for Fluoxetine Capsules
Mylan Laboratories Inc. (NYSE: MYL) announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Fluoxetine Capsules USP, 40 mg.
Advertisement

Fluoxetine Capsules are the generic version of Eli Lilly and Company's Prozac(R) Capsules. Fluoxetine Capsules had U.S. sales of approximately $118 million for the 12 months ending March 31, 2007, for the 40 mg strength.

Advertisement
This product will be shipped immediately.

Mylan previously received approval and is currently marketing the 10 mg and 20 mg strength of fluoxetine capsules.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

Source: PR Newswire
SRM/B
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All